#1 Clinical Trials Search in Europe

Etamsylate

Etamsylate, an antihemorrhagic agent, is being studied in various clinical trials to assess its effectiveness in reducing blood loss during surgical procedures. This article explores the ongoing research on Etamsylate’s potential benefits in different medical contexts, including postpancreatectomy hemorrhage, postpartum hemorrhage, and myomectomy. Understanding these trials can provide valuable insights into the drug’s possible applications and its role in improving patient outcomes.

Table of Contents

What is Etamsylate?

Etamsylate is a medication used to control bleeding. It’s also known by other names such as Dicynone or ethamsylate. This drug belongs to a class of medications called antihemorrhagics, which means it helps to stop or reduce bleeding[1].

How Does Etamsylate Work?

Etamsylate works in several ways to help control bleeding:

  • It increases the resistance of small blood vessels (capillaries), making them less likely to bleed.
  • It helps platelets (small blood cells that help form clots) stick together better.
  • It reduces the production and action of substances called prostaglandins, which can cause platelets to separate and blood vessels to widen and become more permeable (leaky)[1].
All these actions together help to reduce bleeding and promote blood clotting.

Medical Uses of Etamsylate

Etamsylate is used in various medical situations to control bleeding. Some of its uses include:

  • Postpancreatectomy Hemorrhage (PPH): This is bleeding that can occur after surgery to remove all or part of the pancreas. Researchers are studying whether giving etamsylate through a tube into the stomach after this surgery can reduce the risk of bleeding[1].
  • Postpartum Hemorrhage (PPH): This is excessive bleeding after childbirth. Studies are looking at whether giving etamsylate along with other medications can help prevent this type of bleeding in women having cesarean sections (C-sections)[2][3].
  • Surgical Blood Loss: Etamsylate is being studied to see if it can reduce blood loss during and after certain surgeries, such as myomectomy (a surgery to remove uterine fibroids)[4].

How is Etamsylate Administered?

Etamsylate can be given in different ways, depending on the specific medical situation:

  • Through a nasogastric tube: In some cases, such as after pancreas surgery, it may be given through a tube that goes through the nose into the stomach[1].
  • Intravenous (IV) injection: For preventing bleeding during surgery or after childbirth, it may be given as an injection into a vein[2][3].
  • Continuous infusion: In some cases, it may be given as a continuous infusion into a vein for a period of time after surgery[4].
The exact dose and method of administration will be determined by your healthcare provider based on your specific medical condition and needs.

Etamsylate in Combination Therapy

Etamsylate is often used in combination with other medications to enhance its blood-stopping effects. Some common combinations include:

  • Etamsylate and Tranexamic Acid: This combination is being studied for preventing bleeding after childbirth and during certain surgeries[2][3][4].
  • Etamsylate with Oxytocin or other medications: In obstetrics, etamsylate may be used alongside drugs like oxytocin, which helps the uterus contract after childbirth[3].
These combinations are designed to provide more comprehensive control of bleeding in various medical situations.

Ongoing Research and Clinical Trials

Several clinical trials are currently underway to further understand the benefits of etamsylate in different medical scenarios:

  • A study is looking at whether etamsylate can reduce bleeding after pancreas surgery[1].
  • Research is being conducted on the use of etamsylate in combination with other drugs to prevent excessive bleeding after C-sections[2][3].
  • Another study is comparing the effectiveness of etamsylate and other methods in reducing blood loss during surgery to remove uterine fibroids[4].
These ongoing studies aim to provide more evidence about the effectiveness and safety of etamsylate in various medical situations.

Aspect Details
Drug Name Etamsylate
Primary Use Antihemorrhagic agent to reduce blood loss during surgical procedures
Mechanism of Action Increases capillary resistance, stimulates platelet adhesion, inhibits prostaglandin synthesis
Surgical Procedures Studied Postpancreatectomy (Whipple procedure), Cesarean section, Myomectomy
Administration Methods Intravenous injection, Continuous infusion
Combination Therapies Often studied with Tranexamic acid
Primary Outcomes Measured Intraoperative and postoperative blood loss, need for blood transfusion
Secondary Outcomes Hemoglobin levels, duration of hospital stay, perioperative blood pressure
Potential Benefits Reduced blood loss, decreased transfusion needs, lower risk of bleeding-related complications
Current Status Under investigation in multiple clinical trials

FAQ

  • What is Etamsylate and how does it work? Etamsylate is an antihemorrhagic agent that works by increasing the resistance in the endothelium of capillaries and stimulating platelet adhesion. It also inhibits the synthesis and action of prostaglandins, which can cause platelet disaggregation, vasodilation, and increased capillary permeability. These actions help to reduce bleeding.
  • In which surgical procedures is Etamsylate being studied? Etamsylate is being studied in various surgical procedures, including postpancreatectomy (Whipple procedure), cesarean section, and myomectomy (removal of uterine fibroids). These trials aim to assess its effectiveness in reducing blood loss during and after these operations.
  • How is Etamsylate administered in these clinical trials? The administration of Etamsylate varies depending on the study. In some trials, it is given intravenously before the surgical procedure. For example, in one study, 500 mg of Etamsylate is administered intravenously 10 minutes before skin incision. In other cases, it may be given as a continuous infusion for a certain period after surgery.
  • Is Etamsylate used alone or in combination with other drugs? In some clinical trials, Etamsylate is used in combination with other drugs. For instance, it is being studied in combination with Tranexamic acid for preventing postpartum hemorrhage in cesarean sections. The combination of these drugs is being compared to placebo or other standard treatments.
  • What are the potential benefits of using Etamsylate in surgical procedures? The potential benefits of using Etamsylate in surgical procedures include reduced blood loss during and after surgery, decreased need for blood transfusions, lower risk of postoperative complications related to bleeding, and potentially shorter hospital stays. However, it's important to note that these benefits are still being studied and evaluated in clinical trials.

Ongoing Clinical Trials on Etamsylate

  • Study on Andexanet Alfa for Patients on Factor Xa Inhibitors (Apixaban, Rivaroxaban, Edoxaban) Needing Urgent Surgery to Reduce Bleeding Risk

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark Estonia +13

Glossary

  • Etamsylate: An antihemorrhagic agent that works by increasing capillary resistance and promoting platelet adhesion, used to reduce bleeding in various medical conditions and surgical procedures.
  • Postpancreatectomy hemorrhage (PPH): Bleeding that occurs after the surgical removal of part or all of the pancreas, which can be a serious complication of pancreatic surgery.
  • Whipple procedure: A complex surgical operation to remove the head of the pancreas, the first part of the small intestine, the gallbladder, and the bile duct, often performed to treat pancreatic cancer.
  • Pancreatogastrostomy (PG): A surgical procedure where the remaining pancreas is connected to the stomach after partial removal of the pancreas.
  • Pancreatojejunostomy (PJ): A surgical procedure where the remaining pancreas is connected to the jejunum (part of the small intestine) after partial removal of the pancreas.
  • Postpartum hemorrhage: Excessive bleeding after childbirth, typically defined as blood loss of 500 ml or more within 24 hours after delivery.
  • Tranexamic acid: An antifibrinolytic medication used to treat or prevent excessive blood loss from various medical conditions and surgical procedures.
  • Myomectomy: A surgical procedure to remove uterine fibroids (leiomyomas) while preserving the uterus.
  • Leiomyomas: Benign smooth muscle tumors that can develop in the uterus, also known as uterine fibroids.
  • Hemoglobin: A protein in red blood cells that carries oxygen throughout the body, often measured to assess blood loss or anemia.

References

  1. https://clinicaltrials.gov/study/NCT06190535
  2. https://clinicaltrials.gov/study/NCT02604719
  3. https://clinicaltrials.gov/study/NCT04656067
  4. https://clinicaltrials.gov/study/NCT05806307